Pfizer Inc. (PFE) beat its EPS estimates by 27% in the 2022 third quarter. Moreover, the U.S. Food and Drug Administration recently granted Emergency Use Authorization to PFE and BioNTech SE’s (BNTX) Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, the third 3-µg dose in the three-dose primary series for children aged six months to four years of age.
This approval is yet another feather in the cap of PFE. The company has been a significant beneficiary of the pandemic.
